Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of GBCAs for Portable MR Imaging Systems
NCT07296263Active, not recruiting
- Sponsor
- Hyperfine
- Start
- Dec 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of gadolinium in brain lesion, sponsored by Hyperfine. Primary endpoints: Radiologist-rated lesion border delineation on post-contrast portable MRI at 6 months, Radiologist-rated lesion internal morphology visibility on post-contrast portable MRI at 6 months and 1 more. Started Dec 2025; status: active, not recruiting.
02
Drugs
gadolinium
03
Conditions
brain lesion
Beyond the preview
Go deeper on NCT07296263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07296263.